Emergent BioSolutions (EBS) Net Cash Flow (2010 - 2026)

Emergent BioSolutions' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$47.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 199.37% year-over-year to -$47.6 million in Q1 2026; TTM through Mar 2026 was $7.9 million, a 89.4% decrease from a year earlier, with the FY2025 full-year figure at $103.4 million, up 1795.08% from the prior year.
• Net Cash Flow slipped to -$47.6 million in Q1 2026 per EBS's latest filing, from -$40.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $400.5 million in Q4 2022 and bottomed at -$343.6 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$32.7 million (2024), against an average of -$24.4 million.
• Across the five-year window, Net Cash Flow sank 338.27% in 2023 and surged 4594.74% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at $400.5 million in 2022, then plunged by 93.66% to $25.4 million in 2023, then sank by 300.0% to -$50.8 million in 2024, then increased by 21.06% to -$40.1 million in 2025, then fell by 18.7% to -$47.6 million in 2026.
• Per Business Quant, the three latest EBS Net Cash Flow figures stand at -$47.6 million (Q1 2026), -$40.1 million (Q4 2025), and -$21.6 million (Q3 2025).